EnXtra®,
does it really help with Improved caffeine-free alertness, attention, and sustained energy?
research showsEnXtra® is rated C. A 59-person crossover trial in 2017 and a 12-week trial published in 2021 reported signals on an acute attention task or perceived alertness, and a 2026 trial in sleep-restricted adults also found improvements at selected alertness and fatigue time points. All research is concentrated in the EnXtra® branded ingredient and its developer or contracted research network, with multiple time points, subjective scales, selective positive findings, and inconsistent sustained-attention tasks. Independent evidence does not establish clinically sustained energy or improved day-to-day fatigue without caffeine, so the maximum-C ceilings under rules ① and ②-b apply.
ads claimMarketing combines a few hours of test scores and perceived alertness into caffeine-free sustained energy, no crash, and all-day focus. The studies concern selected testing times in healthy caffeine users or sleep-restricted adults and do not establish work productivity or treatment of chronic fatigue.
Useful facts when choosing a product
- EnXtra® is a proprietary standardized extract and is not interchangeable with whole Alpinia galanga or generic galangal powder. Branded-ingredient evidence cannot automatically be transferred to other extracts.
- Acute studies generally used 300 mg of EnXtra®, while the 12-week safety study evaluated 600 mg daily. These are research conditions, not a universal personal dose or validation of every combination product.
- Caffeine-free does not mean free of stimulation or interactions. Adequate clinical data are lacking for pregnancy, lactation, liver or kidney disease, and drug interactions.
- The 12-week trial reported no significant worsening of ECG, blood pressure, or heart rate, but participants were mostly healthy adults. Long-term and vulnerable-population safety remains uncertain, and combination-product labels must be checked separately for caffeine.
What the research actually shows
Srivastava et al. 2017 crossed 59 healthy habitual caffeine users through 300 mg EnXtra®, caffeine, the combination, and placebo. EnXtra® favored the three-hour alerting score, but mental fatigue did not clearly improve and sustained-attention benefit was mainly reported for the caffeine combination. The 12-week Srivastava et al. 2021 study found no important ECG or hemodynamic change and reported perceived alertness and calmness gains, while daytime-sleepiness change was nonsignificant. Pandit et al. 2026 studied 128 sleep-restricted adults in an acute crossover stage and 127 in a 28-day parallel stage; selected alertness and fatigue time points favored the extract, but sustained-attention and hand-function tests were inconsistent. All three reports are commercially connected to EnXtra®.
Why this is classified as C (51)
Positive human trials on an acute objective attention task and perceived alertness or fatigue make D or an unknown grade inappropriate. The entire evidence base remains concentrated in the same branded ingredient and related research network, with subjective scales, multiple-time-point selective positives, and null findings on some cognitive tasks. Rules ① and ②-b therefore cap the grade at C with 51 points; safety is recorded separately as caution.
Counterpoint. The identical ingredient may provide short-term alertness support for healthy adults who prefer to avoid caffeine. It should not be treated as sustained-energy therapy until an independent trial reproduces a prespecified single primary endpoint and real-world work or fatigue-recovery outcomes.
Rejudgment record. New verdict — Accepted positive human alertness signals but applied the maximum-C ceiling under rules ① and ②-b for subjective and multiple-time-point outcomes plus branded-developer concentration
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Acute perceived alertness and attention | C | Positive signals have repeated, but evidence is concentrated in the branded commercial network and selected time points. |
| Clinically meaningful sustained energy or fatigue improvement | C | Selected subjective fatigue times were positive in 2026, but real-world function and chronic-fatigue outcomes are absent and objective sustained attention was mixed. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Srivastava S et al. 2017 | Randomized double-dummy double-blind placebo-controlled four-condition crossover trial | 59 | Two authors were affiliated with Enovate Biolife; proprietary E-AG-01 ingredient | Attention Network Test alerting score, sustained attention, mental fatigue, and sleep | EnXtra® alone favored the three-hour alerting score, but mental fatigue was unclear and sustained-attention benefit was mainly seen with caffeine combination. | Key acute human efficacy evidence with developer concentration |
| Srivastava S et al. 2021 | Randomized double-blind placebo-controlled 12-week parallel trial | Authors from Enovate Biolife clinical development and Vedic Lifesciences | Bond-Lader alertness and calmness, ECG, blood pressure and heart rate, PSQI, and Epworth scores | Perceived alertness and calmness improved, but daytime sleepiness did not significantly change and ECG or hemodynamic worsening was not observed. | Subjective efficacy and short-term safety evidence | |
| Pandit KD et al. 2026 | Randomized double-blind placebo-controlled acute crossover and 28-day parallel trial | 127 | Authors affiliated with OmniActive Health Technologies and Vedic Lifesciences | ANT alertness, Samn-Perelli fatigue, CPT sustained attention, and hand function | Alertness and subjective fatigue improved at selected times, but CPT and hand-function outcomes were not consistently significant. | Latest supporting evidence with commercial links and multiple outcomes |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] EnXtra® x caffeine-free alertness, attention, and sustained energy — Evidence Grade C·51. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/enxtra-caffeine-free-alertness-attention-sustained-energy/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.